UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
Commission File Number: 333-130729
----------
(Check One):[X] Form 10-KSB [ ] Form 10-Q and Form 10-QSB[ ]
Form 20-F [ ] Form 11-K [ ] Form N-SAR
For Period Ended: May 31, 2006
------------------------
[ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended:
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART I - REGISTRANT INFORMATION
ARTHRO PHARMACEUTICALS INC.
--------------------------------
Full Name of Registrant
-------------------------
Former Name if Applicable
3316 West 1st Avenue
---------------------------------------------------------
Address of Principal Executive Office (Street and Number)
Vancouver, British Columbia, V6R 1G4, Canada
-------------------------
City, State and Zip Code
PART II - RULES 12b-25(b) and (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
[X] (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
[X] (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
[ ] (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
State below in reasonable detail the reasons why the Form 10-K and Form 10-KSB, 11-K, 20-F, 10-Q and Form 10-QSB, N-SAR, or other transition report or portion thereof, could not be filed within the prescribed period.
The report of Arthro Pharmaceuticals Inc. on Form 10-KSB could not be filed within the prescribed time period because the Company is experiencing delays in the collection and processing of financial and other information required to be included in the Form 10-KSB. As a result, the Company could not solicit and obtain the necessary review and signatures thereto in a timely fashion prior to the due date of the report. The Form 10-KSB will be filed as soon as practicable and within the 15 day extension period.
PART IV - OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this notification
Peter Robert Hughes (604) 732-8455
-------------------------------------------------------------
(Name) Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), been
filed. If answer is no, identify report(s). [X] YES [ ] NO
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statement to be included in the subject
report or portion thereof? [ ] YES [X] NO
If so, attach an explanation of the anticipated change, both narratively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
ARTHRO PHARMACEUTICALS INC.
--------------------------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
August 30, 2006 By /s/ Peter Robert Hughes
----------------------------------------------
Peter Robert Hughes
Director/President & Chief Executive Officer
